Oxamniquine in the treatment of various schistosome infections in South Africa.
Trials of a new schistosomicide oxamniquine (Vansil) were carried out in the lowveld of the Eastern Transvaal. After initial dose-finding trials, the safety and efficacy of oxamniquine against Schistosoma mansoni at an oral dose of 15 mg/kg twice a day for 2 days (total dose 60 mg/kg), were confirmed. No detectable effect was noted against S. haematobium or S. mattheei.
D000293:Adolescent; D002648:Child; D002986:Clinical Trials as Topic; D004305:Dose-Response Relationship, Drug; D006801:Humans; D009600:Nitroquinolines / Q000627:therapeutic use*; D010073:Oxamniquine / Q000008:administration & dosage / Q000627:therapeutic use*; D010270:Parasite Egg Count; D012548:Schistosoma haematobium / Q000187:drug effects; D012550:Schistosoma mansoni / Q000187:drug effects; D012552:Schistosomiasis / Q000188:drug therapy*
D009600:Nitroquinolines; D010073:Oxamniquine